Tags

Type your tag names separated by a space and hit enter

[Associated psychotropic drugs in deficit schizophrenia].

Abstract

Therapy with classical neuroleptics is not effective enough and its adverse effects are quite disabling, especially in chronic or negative schizophrenia; that is probably why adjunctive therapy is so common. Still conclusive evidence concerning the potential benefit of one or another therapeutic association is scarce. Intrinsic heterogeneity of schizophrenias and tremendous methodological problems constitute plausible explanations. Besides studies are usually realised among unselected patients. Available data about adjunctive therapy with anticholinergics, propranolol, antidepressants, benzodiazepines, lithium and carbamazepine are briefly reviewed here.

Authors+Show Affiliations

Hôpital Corentin Celton, Issy-les-Moulineaux.

Source

L'Encephale 22 Spec No 2: 1996 Jun pg 41-3

MeSH

Antipsychotic Agents
Depression
Drug Therapy, Combination
Humans
Psychotropic Drugs
Schizophrenia
Schizophrenic Psychology
Treatment Outcome

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

8767041

Citation

Beaufils, B. "[Associated Psychotropic Drugs in Deficit Schizophrenia]." L'Encephale, vol. 22 Spec No 2, 1996, pp. 41-3.
Beaufils B. [Associated psychotropic drugs in deficit schizophrenia]. Encephale. 1996;22 Spec No 2:41-3.
Beaufils, B. (1996). [Associated psychotropic drugs in deficit schizophrenia]. L'Encephale, 22 Spec No 2, pp. 41-3.
Beaufils B. [Associated Psychotropic Drugs in Deficit Schizophrenia]. Encephale. 1996;22 Spec No 2:41-3. PubMed PMID: 8767041.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Associated psychotropic drugs in deficit schizophrenia]. A1 - Beaufils,B, PY - 1996/6/1/pubmed PY - 1996/6/1/medline PY - 1996/6/1/entrez SP - 41 EP - 3 JF - L'Encephale JO - Encephale VL - 22 Spec No 2 N2 - Therapy with classical neuroleptics is not effective enough and its adverse effects are quite disabling, especially in chronic or negative schizophrenia; that is probably why adjunctive therapy is so common. Still conclusive evidence concerning the potential benefit of one or another therapeutic association is scarce. Intrinsic heterogeneity of schizophrenias and tremendous methodological problems constitute plausible explanations. Besides studies are usually realised among unselected patients. Available data about adjunctive therapy with anticholinergics, propranolol, antidepressants, benzodiazepines, lithium and carbamazepine are briefly reviewed here. SN - 0013-7006 UR - https://www.unboundmedicine.com/medline/citation/8767041/[Associated_psychotropic_drugs_in_deficit_schizophrenia]_ L2 - http://www.diseaseinfosearch.org/result/6442 DB - PRIME DP - Unbound Medicine ER -